UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): June 18, 2019

 

 

 

Global Blood Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-37539   27-4825712

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080

(Address of Principal Executive Offices) (Zip Code)

 

(650) 741-7700

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share GBT The NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The proposals set forth below were submitted to the stockholders at the 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of Global Blood Therapeutics, Inc. (the “Company”) held on June 18, 2019, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2019 (the “Proxy Statement”).

 

The number of shares of common stock entitled to vote at the Annual Meeting was 56,403,817. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 48,900,897. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.

 

Proposal 1 – Election of Directors

 

The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2022 Annual Meeting of Stockholders or until their successors are duly elected and qualified.

 

Director Nominee   Votes For   Votes Withheld
Ted W. Love, M.D.     33,900,332       6,666,353  
Glenn F. Pierce, M.D., Ph.D.     33,862,606       6,704,079  
Dawn Svoronos     40,213,363       353,322  

 

There were 8,334,212 broker non-votes regarding this proposal.

 

Proposal 2 – Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers as Disclosed in the Proxy Statement

 

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

 

Votes For   Votes Against   Abstentions
  39,475,360       1,058,240       33,085  

 

There were 8,334,212 broker non-votes regarding this proposal.

 

Proposal 3– Ratification of Appointment of Independent Registered Accounting Firm

 

The Company’s stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2019.

 

Votes For   Votes Against   Abstentions
  48,777,590       116,871       6,436  

 

There were no broker non-votes regarding this proposal.

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
  Global Blood Therapeutics, Inc.  
       
Date: June 20, 2019 By: /s/ Tricia Suvari  
   

Tricia Suvari

 
    Chief Legal Officer